Could Wegovy Raise Optic Nerve Risk?
A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.
By
Kerri Miller
March 11, 2026
Clinical Scorecard: Could Wegovy Raise Optic Nerve Risk?
At a Glance
Category Detail
Condition Ischemic Optic Neuropathy (ION) Key Mechanisms Potential dose-dependent effects on optic nerve perfusion, intravascular volume contraction, hypotension, or autonomic instability. Target Population Patients using semaglutide formulations, particularly higher-dose Wegovy. Care Setting Outpatient settings where GLP-1 receptor agonists are prescribed.
Key Highlights
Wegovy (2.4 mg) has a 4.7-fold higher odds of ION compared to Ozempic (1 mg). Men have 3.3-fold higher odds of reported ION than women. No ION reports were identified with oral semaglutide (Rybelsus). Tirzepatide formulations showed no detectable ION reporting signal. The analysis is based on over 30 million FAERS reports. Guideline-Based Recommendations
Diagnosis
Monitor for symptoms of ION in patients prescribed semaglutide. Management
Consider individualized GLP-1 therapy based on risk factors. Monitoring & Follow-up
Conduct longitudinal pharmacoepidemiologic studies for better risk stratification. Risks
Increased risk of ION with higher-dose semaglutide formulations. Patient & Prescribing Data
Patients with obesity or type 2 diabetes prescribed semaglutide.
Wegovy has a stronger reporting signal for ION compared to Ozempic.
Clinical Best Practices
Evaluate patient history for risk factors before prescribing higher doses of semaglutide. Educate patients on potential visual symptoms and the importance of reporting them. References
